Stay connected and up-to-date on the latest news and reports. It’s never been easier to know what’s going on in digital health.
.png)
Pear Therapeutics announced last week that they are looking into “strategic alternatives” that could bolster its current precarious financial situation. Pear has been on the public markets since late 2021, however, its stock price has declined over the last two years.
Read more
FDIC's decision to close SVB has had an immediate impact on startup and tech companies, including those in digital health. With rising interest rates, investors have become increasingly conservative with their investments, focusing on a more targeted investment strategy.
Read more.png)
Mental health has been a pioneering area for digital therapeutics and a keen area of focus for digital health in recent years. As per the latest industry reports, the global market for digital biomarkers is growing, with its value estimated to reach $16,174 million by 2028.
Read more%20(1).png)
There was a wide range of topics discussed at our HealthXL meetings this February. To make sure you’re not missing out on the insightful discussions between community members and to keep you plugged into the conversation, here are Tess' five meeting takeaways from the past month.
Read more.png)
A key component to ensuring the adoption of digital health products is market access and reimbursement. In this week’s blog, we explore France's new fast-track reimbursement pathway for digital health and how it compares to Germany's DiGA pathway.
Read more
The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges. In our most recent sprint, we discussed the pharma sales models for DTx-drug combination products. In this blog, we’ve pulled out the top takeaways from this series.
Read more
Over the past month, our HealthXL community members have discussed the opportunities for digital health in retail healthcare, using real-world data (RWD) to increase market access and revenue generation in DTx partnerships among other topics. Here's a snapshot of expert insights from these meetings.
Read more.png)
In part two, Jeremy Sohn, Managing Partner at P74 Ventures, continues to explore why the wave of innovation in pharma happened too quickly and the primary forces driving the need for change.
Read more%20(1).png)
HealthXL community members and industry leaders from pharma, digital health companies and decentralized trials providers have come together to create this new tool to help sponsors select the best digital measurement technologies for clinical trial use.
Read more.png)
FDIC's decision to close SVB has had an immediate impact on startup and tech companies, including those in digital health. With rising interest rates, investors have become increasingly conservative with their investments, focusing on a more targeted investment strategy.
Read more
Mental health has been a pioneering area for digital therapeutics and a keen area of focus for digital health in recent years. As per the latest industry reports, the global market for digital biomarkers is growing, with its value estimated to reach $16,174 million by 2028.
Read more.png)
There was a wide range of topics discussed at our HealthXL meetings this February. To make sure you’re not missing out on the insightful discussions between community members and to keep you plugged into the conversation, here are Tess' five meeting takeaways from the past month.
Read more
A key component to ensuring the adoption of digital health products is market access and reimbursement. In this week’s blog, we explore France's new fast-track reimbursement pathway for digital health and how it compares to Germany's DiGA pathway.
Read more.png)
The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges. In our most recent sprint, we discussed the pharma sales models for DTx-drug combination products. In this blog, we’ve pulled out the top takeaways from this series.
Read more
Over the past month, our HealthXL community members have discussed the opportunities for digital health in retail healthcare, using real-world data (RWD) to increase market access and revenue generation in DTx partnerships among other topics. Here's a snapshot of expert insights from these meetings.
Read more.png)
In part two, Jeremy Sohn, Managing Partner at P74 Ventures, continues to explore why the wave of innovation in pharma happened too quickly and the primary forces driving the need for change.
Read more.png)
HealthXL community members and industry leaders from pharma, digital health companies and decentralized trials providers have come together to create this new tool to help sponsors select the best digital measurement technologies for clinical trial use.
Read more